Retina Implant gains approval for extended European clinical trials

Article

Retina Implant's scientific advisory board has approved the expansion of the European clinical trials for its subretinal implants for retinitis pigmentosa patients.

Retina Implant's scientific advisory board has approved the expansion of the European clinical trials for its subretinal implants for retinitis pigmentosa patients.

The trial commenced in Tübingen, Gemany in 2010. The multicentre phase of Retina Implant's second human clinical trial will take place in Germany, Budapest, London and Oxford. The study involves patients keeping the implant in permanently so it can be used in everyday situations.

Nine patients were implanted with Retina Implant's wireless device between May 2010 and July 2011. The findings saw patients presenting with the best visual acuity recorded so far. The majority of patients experienced restored vision for everyday life. Visual perception in dim and bright environments was achieved in a significant number of patients.

Professor MacLaren, professor of ophthalmology at Oxford University Hospitals NHS Trust, said, "We are delighted to be involved in testing this pioneering subretinal implant technology. The results achieved by the Retina Implant team to-date represent a significant advance in this technology that could greatly enhance the quality of life for people with an incurable, blinding disease."

Dr Walter G. Wrobel, CEO of Retina Implant, said, "We are pleased that after reviewing the results of the first nine patients in the trial, the scientific advisory board is in agreement that the next stage of our research should begin. The Board's continued support reinforces the progress Retina Implant continues to make on our journey to permanently restore useful vision to retinitis pigmentosa patients."

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.